Clonazolam or Clonitrazolam is a novel depressant that belongs to the class of benzodiazepines. It produces sedative, hypnotic, amnesic and anti-convulsant properties when administered. This is a designer chemical drug which is derived from FDA approved drugs namely Clonazepam and alprazolam.
The usual way of administration of Clonazolam is oral. The threshold range of the drug is 50 – 75 µg, common range seemed to be 200 – 400 µg and a heavier one ranging from 600 – 1000 µg and greater than 1000 µg. The activity and effect of Clonazolam lies up to 6 – 10 hrs with an onset effect of 10 – 30min after the administration.
Clonazolam side effects:
- Cross-tolerance with all benzodiazepines
- Delusions and Dizziness
- Dream potentiation
- Dream suppression
- Extremely physically and psychologically addictive
- Full tolerance is reached within a couple of days of continuous use
- Increased libido
- Low toxicity
- Motivation suppression
- Motor control loss
- Muscle relaxation
- Potentially lethal
- Respiratory depression
- Returns to baseline after 7 – 14 days
- Thought deceleration
- Thought disorganization
Clonazolam usually has a low toxicity relative to dose. However, it is potentially lethal when mixed with depressants like alcohol and opioids. It is strongly recommended that one use harm reduction practices, such as volumetric dosing to ensure the accurate administration of the intended dose. Clonazolam is taken as exceedingly physical and psychological addictive. Clonazolam presents cross-tolerance with all benzodiazepines, meaning that after its consumption all benzodiazepines will have a reduced effect. Tolerance will be developed to the sedative-hypnotic effects within a couple of days of continuous use. After cessation, the tolerance returns to baseline in 7 – 14 days.
The discontinuation and withdrawal of Benzodiazepines is highly impossible and difficult. It is a potential life threatening drug for individuals who are in regular use. An increased risk of high blood pressure, seizures and finally death will occur. The products which lower seizure threshold should not be used at the time of withdrawal. A rebound stimulation showing anxiety, insomnia and restlessness will occur due to its discontinuation. The duration and severity of withdrawal symptoms depend on a number of factors including the half-life of the substance used, tolerance and the duration of abuse. Benzodiazepines with longer half-lives will exhibit withdrawal symptoms with a slow onset and extended duration.
Dangerous interactions: Although many psychoactive substances are safe on their own, they can become dangerous and even lethal when combined with other substances. Certain combinations may be safe in low doses of each but still increase the potential risk of death. Autonomous research should always be done to ensure that a combination of two or more substances is safe before consumption.
The combination of butanediol, alcohol, benzodiazepines, barbiturates and opioids potentiates the amnesia, sedation, muscle relaxation and respiratory depression. At higher concentrations, it can lead to sudden loss of consciousness and depressed respiration thereby increasing the risks of vomiting and dying as a resulted suffocation. It can be dangerous to combine depressants and stimulants due to the risk of accidental excessive intoxication. Stimulants mask the sedative effect of depressants, which is the main factor to gauge the level of intoxication.